LAVA Medtech Acquisition (LVACW) 10-Q2022 Q3 Quarterly report

Filed: 14 Nov 22, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll freshman Bad

New words: abandon, absent, abuse, anniversary, announce, announcing, appealing, avoidance, Biden, burdensome, China, climate, composition, conflict, constrain, content, criteria, Department, dollar, domestic, excise, exclusively, expressed, foreign, geopolitical, hand, harbor, imposed, increase, increased, increasing, inflation, instruct, IR, IRA, lead, levied, mitigate, modify, national, offset, pending, PIPE, portfolio, President, prevent, prohibited, reduction, regulatory, repurchase, repurchased, repurchasing, safe, satisfy, Taiwan, test, thereof, thereunder

Removed: November

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

LVACW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of LAVA Medtech Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Vasco Larcina, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2022
	/s/ Vasco Larcina
	Vasco Larcina
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.